Spectrum of factor IX gene mutations causing haemophilia B from India

Haemophilia B is an X-linked recessively inherited disease caused by highly heterogeneous mutations in the factor IX gene. Very few studies are available on the nature of mutations in haemophilia B patients from India. The present study was undertaken with an aim to characterize the mutations present in haemophilia B patients from western India. The screening for mutations was done by conformation sensitive gel electrophoresis which was subsequently confirmed by DNA sequencing. A total of 57 mutations were detected in 93 haemophilia B patients – 45 single-base substitutions, one a donor splice, two small deletions and nine nonsense mutations. Seventeen novel mutations and two common mutations were also detected in the present study. Majority of the mutations were located in the exon h of the factor IX gene which codes for the catalytic domain. The spectrum of mutations in haemophilia B patients reported from other parts of India has been compiled and a comprehensive analysis has been presented.

[1]  S. Chavali,et al.  Allelic heterogeneity of molecular events in human coagulation factor IX in Asian Indians , 2007, Human mutation.

[2]  K. Ghosh,et al.  A common G10430A mutation (Gly 60 Ser) in the factor IX gene describes the presence of moderate and mild hemophilia B in the majority of the Gujarati population , 2007, Annals of Hematology.

[3]  M. Chandy,et al.  Molecular characterization of factor IX gene mutations in 53 patients with haemophilia B in India , 2005, Thrombosis and Haemostasis.

[4]  S. Chavali,et al.  Novel missense mutation in the coagulation factor IX catalytic domain associated with severe haemophilia B – Factor IXDelhi , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  K. Ray,et al.  Molecular pathology of haemophilia B: identification of five novel mutations including a LINE 1 insertion in Indian patients , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  F. Rosendaal,et al.  Argatroban inhibits staphylothrombin , 2003, Journal of thrombosis and haemostasis : JTH.

[7]  A. Tordai,et al.  A haemophilia A and B molecular genetic diagnostic programme in Hungary: a highly informative and cost‐effective strategy , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[9]  G. Dolan,et al.  Precise Carrier Diagnosis in Families with Haemophilia A: Use of Conformation Sensitive Gel Electrophoresis for Mutation Screening and Polymorphism Analysis , 1998, Thrombosis and Haemostasis.

[10]  D. Cooper,et al.  Determinants of the factor IX mutational spectrum in haemophilia B: an analysis of missense mutations using a multi-domain molecular model of the activated protein , 1994, Human Genetics.

[11]  D. Bentley,et al.  Direct estimate of the haemophilia B (factor IX deficiency) mutation rate and of the ratio of the sex-specific mutation rates in Sweden , 1992, Human Genetics.

[12]  S. Sommer,et al.  Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States. , 1991, Genomics.

[13]  S. Sommer,et al.  Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene. , 1990, American journal of human genetics.

[14]  G. Castaldo,et al.  Molecular genotyping of the Italian cohort of patients with hemophilia B. , 2005, Haematologica.

[15]  S. Chavali,et al.  Molecular characterization of hemophilia B in North Indian families: identification of novel and recurrent molecular events in the factor IX gene. , 2004, Haematologica.

[16]  J. Leggo,et al.  A Founder Factor VII Mutation, Valine 2016 to Alanine, in a Population with an Extraordinarily High Prevalence of Mild Hemophilia A , 2002, Thrombosis and Haemostasis.

[17]  R. Ljung,et al.  Haemophilia: strategies for carrier detection and prenatal diagnosis. , 1993, Bulletin of the World Health Organization.